L-Isoleucine-amino acid

Hebei Jingye Pharmaceutical Technology Co., Ltd. is a pharmaceutical high-tech enterprise based in China and facing the world. The company is committed to growing into a manufacturer of high-quality salicylic acid and aspirin, focusing on the manufacture, development and service of cardio-cerebrovascular preparations and APIs . There are 4 existing product varieties and 6 reserve varieties, all of which have broad development prospects in the field of cardiovascular and cerebrovascular preparations and APIs.

Hebei Jingye Pharmaceutical Technology Co., Ltd.

Jingye Group is a large-scale group company with steel as its main business and concurrently engaged in deep processing of steel, international trade, powder metallurgy 3D printing, tourism and hotels. It has 23,500 employees and total assets of 39 billion yuan. In 2018, the Group achieved sales revenue of RMB 90.1 billion and tax revenue of RMB 3.35 billion. The Dedicated Group ranks 217 among the top 500 enterprises in the country, and 95 among the top 500 Chinese manufacturing enterprises. The group is a large-scale rebar production base in the world. It was selected as the first batch of green factories in 2017 by the Ministry of Industry and Information Technology, and was rated as the "2017 Beijing-Tianjin-Hebei Most Influential Responsible Brand. The "dedication" trademark is a well-known trademark in China, with a dedicated brand value of 20.668 billion yuan.

The company was founded in 1989 with advanced technological equipment and strong technical force. The main products are the dedicated brand sublimation salicylic acid, medicinal salicylic acid, and aspirin. The company has self-support import and export rights, and its products are sold at home and abroad, and its foreign exports are all over the United States, Russia, Britain, Germany, France and other European and American countries and a large number of Asian countries and regions.

In order to make the pharmaceutical industry bigger and stronger, the new plant is located in the National Technology Development Zone-Beijing·Cangzhou Bohai New Area Biomedical Industrial Park. The new plant covers an area of 100 acres and was heavily built by Tianjin Medical Design Institute with a total investment of 350 million yuan.